Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 5/20 | 0.30 |
| ▸ | F2 | P00734 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075140 | 0.77 | PRCP (0.37) | — | |
| SCHEMBL22263456 | 0.73 | CHRNA7 (0.38) | — | |
| SCHEMBL17075122 | 0.73 | NLRP3 (0.33) | F12 | |
| SCHEMBL17075095 | 0.71 | F12 (0.33) | F12F2 | |
| SCHEMBL22263472 | 0.71 | F10 (0.36) | F2 | |
| SCHEMBL17075112 | 0.70 | KDM1A (0.35) | KDM1AF12 | |
| SCHEMBL2764864 | 0.69 | BCHE (0.34) | KDM1AF12F2 | |
| SCHEMBL30268332 | 0.68 | KDM1A (0.41) | KDM1AF12 | |
| SCHEMBL1140930 | 0.68 | KDM1A (0.41) | KDM1AF12 | |
| SCHEMBL17075101 | 0.68 | NLRP3 (0.32) | F12F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704095-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-09-09 | — | — | EP | disclosed |
| US-20200239420-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200239420-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239420-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | KDM1A 62/4885F12 2092/4885F2 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.